RT Journal Article
SR Electronic
T1 LSO-023 Clinical characteristics of SARS-CoV-2 infection in patients with systemic lupus erythematosus in Argentina: data from the SAR-COVID national registry
JF Lupus Science & Medicine
JO Lupus Sci Med
FD Lupus Foundation of America
SP A48
OP A48
DO 10.1136/lupus-2023-KCR.64
VO 10
IS Suppl 1
A1 Isnardi, Carolina
A1 Roberts, Karen
A1 Tissera, Yohana
A1 Petkovic, Ingrid
A1 Berbotto, Guillermo
A1 Gobbi, Carla
A1 Tanten, Romina
A1 Cogo, Karina
A1 Asnal, Cecilia
A1 Baños, Andrea
A1 Vivero, Florencia
A1 Schmid, Maria Marcela
A1 Lazaro, Ma Alicia
A1 German, Noelia
A1 Takashima, Lorena
A1 Scafati, Julia
A1 Werner, Marina Laura
A1 Casalla, Luciana
A1 Matellan, Carla
A1 Castrillon, Diana Marcela
A1 Rodriguez, Florencia
A1 Moyano, Sebastián
A1 Martin, Maria Luz
A1 Cosentino, Vanesa
A1 Herscovich, Natalia
A1 Tralice, Elda Rossella
A1 Barbich, Tatiana
A1 Vasquez, Dora Lia
A1 Buschiazzo, Emilio
A1 Maid, Pablo
A1 Ledesma, Ana Carolina
A1 Yohena, Victor
A1 Gomez, Gimena
A1 Quintana, Rosana
A1 Pons-Estel, Guillermo J
YR 2023
UL http://lupus.bmj.com/content/10/Suppl_1/A48.1.abstract
AB Background Patients with systemic lupus erythematosus (SLE) present greater severity of SARS-CoV-2 infection compared to the general population. High disease activity and some immunosuppressants have been associated with worse outcomes. The aim of this study was to describe the characteristics of SARS-CoV-2 infection in patients with SLE in Argentina from the SAR-COVID registry and to establish factors associated with a worse outcome.Methods Observational study. Patients diagnosed with SLE with confirmed SARS-CoV-2 infection (RT-PCR and/or positive serology) from the SAR-COVID registry were included. Data was collected from August 2020 to March 2022. The outcome of the infection was measured using the World Health Organization – ordinal scale (WHO-OS). Severe COVID-19 was defined as an WHO-OS value ≥5. Descriptive analysis, Student’s T test, Mann Whitney U, ANOVA, Chi2 and Fisher. Multiple logistic regression.Results A total of 399 patients were included, 93% female, with a mean age of 40.9 years (SD 12.2), 39.6% had at least one comorbidity. At the time of infection, 54.9% were receiving glucocorticoids, 30.8% immunosuppressants, and 3.3% biological agents. SARS-CoV-2 infection was mild in most cases, while 4.6% had a severe course and/or died. The latter had comorbidities, used glucocorticoids and had antiphospholipid syndrome (APS) more frequently and higher disease activity at the time of infection. In the multivariate analysis, high blood pressure (OR 5.1, 95%CI 1.8–15.0), the diagnosis of APS (4.7, 95%CI 1.2–15.8), and the use of glucocorticoids (10 mg/day or more: OR 5.5, 95%CI 1.6–20.5) were associated with severe hospitalization and/or death from COVID-19 (WHO-EO≥5).Conclusions In this cohort of SLE patients with confirmed SARS-CoV-2 infection, most had a symptomatic course, 22.1% were hospitalized, and 5% required mechanical ventilation. Mortality was close to 3%. The diagnosis of APS, having high blood pressure, and the use of glucocorticoids were significantly associated with severe COVID-19.